Evidence mapPaperPMID 42589103Full record

ReviewBiology2026

Natural Product-Derived Carbon Dots in Neurodegenerative Diseases: Advances in Blood-Brain-Barrier-Related Delivery, Neuroprotection, and Theranostics.

Kaixin Song, Xiang Gu, Na Sun, Rujia Xie, Ziyan Chen, Zili Wang, Ya Li, Lei Meng

Abstract readReview
In one paragraph

Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaixin SongSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0009-2195-2127
Xiang GuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Na SunSchool of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Rujia XieSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Ziyan ChenSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Zili WangHunan Drug Evaluation and Adverse Reaction Monitoring Center, Changsha 410013, China.
Ya LiSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0005-8684-9308
Lei MengSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.

Funding

First-Class Discipline of Pharmaceutical Science of Hunan ProvinceHunan Provincial Natural Science Foundation of China 2024JJ8169Hunan University of Traditional Chinese Medicine 2025CX079Pharmaceutical Open Fund of Domestic First-Class Disciplines (Cultivation) of Hunan Province
6 · The paper itself

Abstract

The mechanisms underlying neurodegenerative diseases (NDDs) involve multiple pathological processes, such as abnormal protein aggregation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and the disruption of neurovascular unit homeostasis. The blood-brain barrier (BBB) restricts drug exposure in the brain, posing a significant challenge for central nervous system delivery and for improving therapeutic efficacy. In recent years, carbon dots derived from natural products (CDs) have emerged as candidate materials for brain delivery and theranostic applications due to their small size, modifiable surfaces, fluorescence-tracking capability, and potential neuroprotective activity. This narrative review summarizes their sources, physicochemical characteristics, biological basis, interactions with the BBB, delivery strategies, neuroprotective effects, and imaging applications. Current evidence suggests that these CDs can alleviate oxidative stress and inflammatory responses, influence abnormal protein aggregation, and support drug delivery and fluorescence tracking in certain cellular and animal models. However, BBB permeability, brain fluorescence signals, brain parenchymal exposure, and therapeutic efficacy represent distinct levels of evidence and should not be considered interchangeable. Future studies should focus on strengthening material standardization, ensuring batch-to-batch consistency, characterizing absorption, distribution, metabolism, and excretion (ADME), conducting long-term safety assessments, and validating using humanized BBB models.

Indexed as

blood–brain barrierbrain deliverynatural product-derived carbon dotsneurodegenerative diseasesneuroprotectiontheranostics

Identifiers

PMID42589103
PMCPMC13464885

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.